Survival in patients who received eryaspase on top of low-dose cytarabine was no longer than that for the group that just got chemotherapy alone.
Gilead has made a bolt-on acquisition of Cell Design with an eye to the future of CAR-T.
When payers and biopharma fight over pricing, patients with rare diseases can suffer. See how Real World Evidence and value-based contracts can help.
Orbimed is one of the biggest backers of life science companies in the world with $14 billion in asset management, but today its founder, Sam Isaly, has left…
SAGE-217 triggered near-immediate, fairly durable improvements in patients with major depressive disorder.
Patients with hemophilia B have seen their symptoms controlled for up to a year with a single dose of a gene therapy developed by Spark Therapeutics, almost…
Officials want firms to team up to test multiple candidates in single trials, thereby cutting the number of patients who receive placebos.
Metacrine is adding to this week's NASH talk after getting off a series B as it aims to combat the fatty liver disorder.
Carmot will use its lead-identification technology to provide Amgen with a stream of prospects against conditions including Parkinson’s disease.
Michael Gilman retired when Padlock Therapeutics was bought out, but now he’s back to helm a company promising to transform cell and gene therapies.
The document details planned investments from drug developers including GlaxoSmithKline, although many of the commitments are vague or already known.